Further work will be required to evaluate whether elevated WNT11 is necessary or sufficient to cause the mesenchymal transition associated with long-term antiangiogenic therapy of glioma tumor tissue in vivo46. This evidence concerns the gene WNT11 and central nervous system cancer.